International study shows wide differences in 5-year survival rates across the globe
the ONA take:
According to a new study published in the journal The Lancet, there are very large differences in 5-year survival among patients with cancer between 67 countries.
For the CONCORD-2 study, researchers used patient data from 279 cancer registries and identified 25.7 million patients with cancer diagnosed with one of the 10 most common cancers, as well as 75,000 children diagnosed with acute lymphoblastic leukemia (ALL) between 1995 and 2009.
Results showed that pediatric patients with ALL had various different 5-year survival rates depending upon what country they reside in. Patients from Indonesia, Jordan, Lesotho, Mongolia, and Tunisia had a 5-year survival rate between 16% and 50%, while patients in Austria, Belgium, Canada, Germany, and Norway had a 5-year survival rate over 90%.
Among the 10 most common cancers, Israel and Ecuador had the highest survival for colon cancer (≥68%); Cyprus, Iceland, and Japan had the highest for rectal cancer (≥70%); and Australia, Brazil, Canada, Cyprus, Israel, Japan, the U.S. and many European countries had the highest survival for breast cancer (≥85%). Mongolia had the lowest survival for breast, colon, and rectal cancers. In Europe, European Russia had the lowest survival for those three cancers.
There are very large differences in 5-year survival among patients with cancer between 67 countries.
Sign Up for Free e-newsletters
- A Witness to Letting Go: Nursing Care at the End of Life
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- Age Not a Deterrent to Immunotherapy for Malignant Melanoma
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Patients With Head and Neck Cancer Have Greater Chance of Being Prescribed Opioids
- Medical Terms in Patient Education: Using the Confusing to Explain the Complicated
- Bedside Assessment Tool Improves Worst Pain in Patients With Cancer
- Androgen-Deprivation Therapy for Prostate Cancer May Cause Nocturia, Sleep Disturbance
- USPSTF Rates Ovarian Cancer Screening a D for Asymptomatic, Low-Risk Women
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|